Topical vs Transdermal Cannabinoid Products
How topical and transdermal cannabinoid products differ in design and purpose, what research shows about each, and why neither is proven for treating conditions.
Content last updated . This page has not been medically reviewed.
Definitions
- Topical: applied to skin to act on or near the spot, such as a cream, balm, lotion or roll-on. See CBD creams, balms and lotions.
- Transdermal: designed to carry a compound through the skin into the bloodstream for effects beyond the application site. See transdermal patches.
The words are used loosely in marketing. A review of CBD skin trials used both terms together and proposed a framework in which skin blood vessels could carry topical CBD into the blood, drawing parallels between the two routes. [1] So "topical" does not guarantee that nothing is absorbed, and "transdermal" on a label does not prove that anything is.
Side by side
| Question | Topical | Transdermal |
|---|---|---|
| Intended target | Skin and tissue under it | Whole body via blood |
| Typical forms | Creams, balms, lotions, roll-ons | Patches, some gels marketed as transdermal |
| Human blood-level data | The review of eight skin-applied CBD trials found reporting gaps; blood concentration measurement was called mandatory for future work [1] | One small healthy-volunteer study showed CBD and THC in blood, with large variation [2] |
| Human benefit evidence | Mixed, small trials, several null [3][4][5] | Not shown (the study measured levels only) [2] |
| Main skin risks | Irritation or allergy from the product's ingredients | Contact dermatitis from adhesive, drug or enhancers [6] |
Evidence
- Delivery: reviews say skin penetration for cannabinoids is a challenge, with limited clinical trials of delivery systems. [7]
- Animals: a review of peripherally applied cannabinoids for pain found mostly animal data, rated low quality; the human studies were few. [8] That is preclinical evidence.
- Humans: see the linked pages. Label for both routes: insufficient evidence or mixed, depending on the condition.
Is there a winner?
No. The question that matters is not which route is stronger but whether a particular product has been tested for a particular outcome in people. For most skin cannabinoid products it has not. Marketing that implies a route is "more effective" is a marketing claim.Legal and quality notes
In the US the FDA treats products intended to treat disease as drugs and says Epidiolex is the only approved CBD drug (read 2026-10-22; not legal advice). [9] Quality varies: see certificates of analysis and safety of topical products.Frequently asked questions
Does a topical cannabinoid enter the blood?
It may, but the evidence is thin; the review of skin-applied CBD trials said blood measurements are needed. [1]
Which has more evidence for pain?
Neither has solid evidence. Topical trials are mixed; transdermal work measured blood levels only. [4][5][2]
Should I choose by route?
That is a question for your clinician or pharmacist, especially with prescription medicines. See CBD and medication interactions.
References
- Scholfield CN, Waranuch N, Kongkaew C. Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. Cannabis Cannabinoid Res. 2023. Read 2026-10-22.
- Varadi G et al. Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults. Adv Ther. 2023. Read 2026-10-22.
- D'Andre S et al. Topical Cannabidiol for Established Chemotherapy-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Trial. Cannabis Cannabinoid Res. 2024. Read 2026-10-22.
- Haffar A et al. Topical Cannabidiol After Total Knee Arthroplasty Does Not Decrease Pain or Opioid Use: A Randomized Placebo-Controlled Trial. J Arthroplasty. 2022. Read 2026-10-22.
- Heineman JT et al. A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. J Hand Surg Am. 2022. Read 2026-10-22.
- Romita P et al. Contact dermatitis due to transdermal therapeutic systems: a clinical update. Acta Biomed. 2018. Read 2026-10-22.
- Permeation-Enhancing Strategies for Transdermal Delivery of Cannabinoids. Cannabis Cannabinoid Res. 2024. Read 2026-10-22.
- Linde L et al. Efficacy of topical cannabinoids in the management of pain: a systematic review and meta-analysis of animal studies. Reg Anesth Pain Med. 2022. Read 2026-10-22.
- U.S. Food and Drug Administration, FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD): Questions and Answers. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.